Company Overview and News
CALGARY, Alberta, June 05, 2018 (GLOBE NEWSWIRE) -- Shaw Communications Inc. today announced the integration of the YouTube and YouTube Kids apps into its intuitive BlueSky TV platform, marking the latest enhancement to the video experience. Users can now stream videos and keep up with livestreams from the comfort of their couches in a whole new way — revamping the TV and YouTube experience.
SJR.B SJR WIREX SJRWF SJR.PR.A SJR.A
CALGARY, Alberta, May 22, 2018 (GLOBE NEWSWIRE) -- Shaw Communications Inc. (TSX:SJR.B) (TSX:SJR.PR.A) (TSX:SJR.PR.B) (NYSE:SJR) (TSX-V:SJR.A) today announced the successful completion of its first 5G technical trials in Calgary. Conducted in collaboration with Nokia, CableLabs and Rohde & Schwarz, Shaw’s trials leveraged 28GHz mmWave and 3.5GHz spectrum and demonstrated the significant and sustained speeds for the next generation of wireless technology.
SJR.B SJR WIREX SJRWF SJR.PR.A SJR.A
The federal competition watchdog says he wants to "shine a light" on Canada's broadband internet providers with the public's comments on a market that is predominantly served by traditional phone and cable companies.
BCE RCIAF RCI SJR.B BCEXF SJR SJRWF SJR.PR.A TU SJR.A
Telecom has had a rough year, largely thanks to concerns over cord cutting, a price war in wireless, and rising interest rates.
RCI SJR.B SJR SJRWF SJR.A BCE CHTR RCIAF FTRPR SJR.PR.A MOBAF TU FTR
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including UnitedHealth (UNH), Netflix (NFLX) and Caterpillar (CAT). These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.
GD SJR.B CAT DGX INFY SJR NFLX SJRWF THS SJR.A INFY SJR.PR.A UNH LAD
Second Cup $3.61 (Toronto symbol SCU, (OTC:SCUPF); Shares outstanding: 17.04 million; Market cap: $61.52 million; www.secondcup.com) is a Canada-based specialty coffee retailer with 286 cafes of which 12 are company-operated and the remaining are operated by franchisees.
TWMJF SJR.B NACNF WEED SJR CAO SJRWF ADWPF SJR.PR.A SCU SCUPF SJR.A
Rogers Communications Inc. (RCI - Free Report) is set to release first-quarter 2018 results on Apr 19. The company beat the Zacks Consensus Estimate in the trailing four quarters, with an average positive surprise of 4.97%. In fourth-quarter 2017, earnings of 69 cents per share outpaced the Zacks Consensus Estimate by a penny. Although revenues of $2.86 billion lagged the consensus mark, the figure increased 3% year over year driven by solid result from the Wireless segment.
RCI SJR.B APO.PRB APO.PRA WDC MS.PRE SJR MS.PRF SJRWF MS.PRG MS.PRA APO PAYC SJR.A BCE RCIAF MS.PRI MS.PRK SJR.PR.A MS
3h - Asif
Business Arrowhead develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Deemed to be one of the most important recent discoveries in life science with the potential to transform medicine, the discoverers of RNAi were awarded a Nobel Prize in 2006 for their work. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing. In fiscal 2017, Arrowhead refocused its resources on therapeutics that exclusively utilize the company’s Targeted RNAi Molecule (TRiMTM) platform technology. Therapeutics built on the TRiMTM platform have demonstrated high levels of pha...
2018-06-11 - Asif
Overview Proteon Therapeutics is a late-stage biopharmaceutical company focused on the development of novel, first-in-class pharmaceuticals to address the needs of patients with renal and vascular disease. The company's product candidate, vonapanitase, is a recombinant human elastase that Proteon Therapeutics is developing to improve vascular access outcomes in patients with chronic kidney disease, or CKD, undergoing or planning for hemodialysis, a lifesaving treatment that cannot be conducted without a functioning vascular access. The company believe data from its completed Phase 2 and Phase 3 clinical trials of vonapanitase support that a one-time, local application of investigational vonapanitase during surgical creation of a radiocephalic fistula for hemodialysis may improve fistula use for hemodialysis and secondary patency (time to fistula abandonment), thereby improving patient outcomes and reducing the burden on patients and the healthcare system. Arteriovenous fistu...
2018-06-11 - Asif
Overview Galena Biopharma is a clinical-stage biopharmaceutical company focused on novel cancer immunotherapeutics for a broad range of cancer indications. The company's lead product candidate, galinpepimut-S, or GPS, is a cancer i unotherapeutic agent licensed from Memorial Sloan Kettering Cancer Center, or MSK, that targets the Wilms tumor 1, or WT1, protein, which is present in 20 or more cancer types. Based on its mechanism of action as a directly immunizing agent, GPS has the potential as a monotherapy or in combination with other immunotherapeutic agents to address a broad spectrum of hematologic, or blood, cancers and solid tumor indications. Phase 2 clinical trials for GPS have been completed and Galena Biopharma has planned Phase 3 clinical trials (pending funding availability) for two indications, acute myeloid leukemia, or AML, and malignant pleural mesothelioma, or MPM. GPS is also in development as a potential treatment for multiple myeloma, or MM, and ovarian can...